Skip to search formSkip to main contentSkip to account menu

NPI 2358

Known as: (3Z,6Z)-6-benzylidene-3-{[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylidene}piperazine-2,5-dione, NPI-2358, NPI2358 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Diketopiperazines

Narrower (1)

plinabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel
3571 Background: NPI-2358 is a vascular disrupting agent (VDA) that destabilizes tumor vascular endothelial cell architecture… 
2010
2010
Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC).
7592 Background: Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) that acts on the cytoskeleton to destabilize tumor… 
2010
2010
Cancer Therapy : Clinical Phase 1 First-inHuman Trial of the Vascular Disrupting Agent Plinabulin ( NPI-2358 ) in Patients with Solid Tumors or Lymphomas
Purpose: Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural… 
2009
2009
Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel.
3571 Background: NPI-2358 is a vascular disrupting agent (VDA) that destabilizes tumor vascular endothelial cell architecture… 
2009
2009
NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.
Abstract 3842 Poster Board III-778 Background and Rationale Vascular disrupting agents (VDAs) act via selectively disrupting… 
2008
2008
Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
3525 Background: NPI-2358 is a novel vascular disrupting agent (VDA) acting on tubulin dimerization that destabilizes tumor… 
2008
2008
Tubulin Photoaffinity Labeling with Biotin‐Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents
NPI‐2358 (1) is a potent antimicrotubule agent that was developed from a natural diketopiperazine, phenylahistin, which is… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2007
2007
A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358
2007
2007
Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
B14 Background: NPI-2358 is a novel tumor vascular disrupting agent (VDA) acting on β-tubulin that destabilizes tumor vascular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)